Barbieri E, Perini P, Marino P, Zardini P
Division of Cardiology, University of Verona, Italy.
J Heart Lung Transplant. 1995 May-Jun;14(3):572-8.
Prostaglandin E1 has been used in patients undergoing evaluation for heart transplantation. Because of high lung metabolism, the drug has been used to test pulmonary vasoreactivity, although a systemic effect is also present. The purpose of this study is a more thorough assessment of the drug.
Prostaglandin E1 was infused with progressive steps in 14 patients in New York Heart Association class III to IV with severe dilated cardiomyopathy. The patients were studied through a combined hemodynamic and Doppler echocardiographic evaluation.
With prostaglandin E1, mean aortic and pulmonary arterial pressure decreased by 7% (p < 0.01) and 24% (p < 0.001), respectively with a 23% (p < 0.001) increase in stroke volume index. Systemic vascular resistance decreased by 22% (p < 0.001), and pulmonary vascular resistance decreased by 33% (p < 0.001), with a 15% decrease in the pulmonary/systemic vascular resistance ratio. Heart rate was unaffected. Minimum and end-diastolic left ventricular pressure decreased by 35% (p < 0.001) and 21% (p < 0.001), respectively. The logarithmic time constant of left ventricular isovolumetric relaxation and maximum rate of isovolumic pressure decline were not modified. Early and late left ventricle diastolic filling were not significantly modified if considered separately, but there was a 27% (p < 0.01) decrease in the early/late filling ratio, suggesting a redistribution of diastolic filling to later in diastole. The 34% (p < 0.01) decrease in right atrial pressure suggests a reduction in intrapericardial pressure which mirrors the significant change in the early/late ratio toward a less restrictive filling pattern.
It is possible that the end-stage ventricles of these patients respond to the reduction in pulmonary and systemic resistances secondary to prostaglandin E1 infusion by increasing stroke volume, with a redistribution of diastolic filling to later in diastole.
前列腺素E1已用于接受心脏移植评估的患者。由于肺部代谢率高,该药物已被用于测试肺血管反应性,尽管也存在全身效应。本研究的目的是对该药物进行更全面的评估。
对14例纽约心脏协会心功能III级至IV级的重度扩张型心肌病患者逐步输注前列腺素E1。通过联合血流动力学和多普勒超声心动图评估对患者进行研究。
使用前列腺素E1时,平均主动脉压和肺动脉压分别下降7%(p<0.01)和24%(p<0.001),每搏量指数增加23%(p<0.001)。全身血管阻力下降22%(p<0.001),肺血管阻力下降33%(p<0.001),肺/全身血管阻力比值下降15%。心率未受影响。左心室最小和舒张末期压力分别下降35%(p<0.001)和21%(p<0.001)。左心室等容舒张的对数时间常数和等容压力下降最大速率未改变。单独考虑时,左心室舒张早期和晚期充盈无明显改变,但早期/晚期充盈率下降27%(p<0.01),提示舒张期充盈重新分布至舒张后期。右心房压力下降34%(p<0.01),提示心包内压力降低,这反映了早期/晚期比值向限制性较小的充盈模式的显著变化。
这些患者的终末期心室可能通过增加每搏量对前列腺素E1输注引起的肺和全身阻力降低做出反应,舒张期充盈重新分布至舒张后期。